Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Medical Tech’s Test for Bladder Cancer Approved

publication date: Apr 27, 2009

China Medical Technologies (中国医疗技术公司) was granted SFDA approval for a bladder cancer FISH probe, an advanced molecular diagnostic test kit that uses DNA probes for early detection and monitoring of bladder cancer. The probe detects whether human bladder cells show aneuploidy (an unusual number of chromosomes) for chromosomes 3, 7, 17 and loss of the p16 locus. Several China hospitals use the probes for diagnosing patients with hematuria (red blood cells in the urine) and have diagnosed patients with early-stage bladder cancer as well as early-stage ureteral cancer, which caused hematuria in these patients. More details...

Stock Symbol: (NSDQ: CMED)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital